Turkey Pharmaceutical Market to Grow from USD 22.3 Billion to USD 32.6 Billion, Driven by Rising Healthcare Needs

Turkey Pharmaceutical Market Overview:

• Market Size in 2025: USD 22.3 Billion

• Market Size in 2034: USD 32.6 Billion

• Market Growth Rate (CAGR) 2026-2034: 4.19%

According to IMARC Group's latest research publication, "Turkey Pharmaceutical Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2026-2034", the Turkey pharmaceutical market size reached USD 22.3 Billion in 2025. Looking forward, the market is projected to reach USD 32.6 Billion by 2034.

How AI is Reshaping the Future of Turkey Pharmaceutical Market?

• AI-Powered Drug Discovery: Artificial intelligence is helping Turkish pharmaceutical companies analyze molecular structures, identify potential drug candidates, and accelerate research workflows. The country's health technology strategy also identifies AI and advanced data analytics as important components of next-generation healthcare and personalized medicine.

• Predictive Manufacturing and Quality Control: AI-based analytics can monitor production parameters, identify deviations, and support predictive maintenance across pharmaceutical manufacturing facilities. With 109 pharmaceutical and radiopharmaceutical production facilities operating in Türkiye, AI adoption can create significant opportunities for improving production efficiency and quality assurance.

• Personalized Medicine: AI can combine clinical, genomic, and patient data to support more targeted treatment decisions. Türkiye's national health technology strategy highlights the integration of artificial intelligence, omics technologies, and personalized medicine as an opportunity for developing smarter healthcare systems.

• Supply Chain Optimization: Machine learning can help pharmaceutical manufacturers forecast demand, manage inventories, optimize distribution routes, and reduce the risk of medicine shortages. This is particularly relevant to Türkiye's large domestic pharmaceutical network, which produces more than 14,300 products and exports medicines to over 186 countries.

• Clinical Research and Drug Safety: AI-enabled platforms can support patient recruitment, clinical data analysis, adverse-event monitoring, and pharmacovigilance. These capabilities can help pharmaceutical companies improve research productivity while strengthening regulatory and patient-safety processes.

Grab a sample PDF of this report: https://www.imarcgroup.com/turkey-pharmaceutical-market/requestsample

Turkey Pharmaceutical Market Trends & Drivers:

Turkey pharmaceutical market is being supported by expanding domestic healthcare demand, a well-established manufacturing base, and increasing investment in advanced pharmaceutical products. The industry comprises around 820 companies, while pharmaceutical and radiopharmaceutical production facilities, raw material plants, and related manufacturing infrastructure provide a broad industrial ecosystem. The sector employs nearly 50,000 people and offers more than 14,300 pharmaceutical products. Türkiye also maintains regulatory alignment with European Union directives, supporting international market access and manufacturing standards.

The increasing importance of biotechnology and specialty medicines is creating new opportunities across the Turkish pharmaceutical industry. Biotechnological products represented 18.8% of prescription products by value, reaching TRY 60.9 billion across 40 million units. The biosimilar segment has also attracted significant attention as manufacturers seek to improve access to advanced therapies while supporting domestic production capabilities. Türkiye's health technology strategy identifies biotechnology, biosimilars, cell and gene therapies, and high-value pharmaceutical production as strategic areas for industrial development.

Government support is further strengthening pharmaceutical manufacturing, localization, and research activities. Türkiye's new investment incentive framework identifies active pharmaceutical ingredients as a strategic investment area, while healthcare-related investments can receive extensive support through tax, social security, financing, and customs-related incentives. In addition, the Technology-Focused Industrial Move Program has supported projects covering biosimilar, oncology, autoimmune, and innovative generic medicines. The Ministry of Industry and Technology reported that 161 healthcare-industry investments received incentive certificates and that more than TRY 70 billion in investment was mobilized.

Turkey Pharmaceutical Industry Segmentation:

The market report offers a comprehensive analysis of the segments, highlighting those with the largest Turkey pharmaceutical market share. It includes detailed market assessment across the following segments.
The report has segmented the market into the following categories:

Drug Type Insights:

• Generic Drugs
• Branded Drugs

Therapeutic Area Insights:

• Genito-Urinary Drugs
• Hematology Drugs
• Anti-Infective Drugs
• Metabolic Disorder Drugs
• Musculoskeletal Disorder Drugs
• Central Nervous System Drugs
• Oncology Drugs
• Ophthalmology Drugs
• Respiratory Diseases Drugs

Biologics Insights:

• Monoclonal Antibodies (MAbs)
• Therapeutic Proteins
• Vaccines

Nature Insights:

• Organic
• Conventional

Regional Insights:

• Marmara
• Central Anatolia
• Mediterranean
• Aegean
• Southeastern Anatolia
• Black Sea
• Eastern Anatolia

Regional Insights:

The Marmara region represents an important pharmaceutical hub because of its concentration of manufacturing, research, healthcare, logistics, and commercial infrastructure, particularly around Istanbul. Central Anatolia also plays a significant role through Ankara's healthcare and research ecosystem. Meanwhile, the Mediterranean and Aegean regions benefit from established healthcare infrastructure and proximity to major domestic and international transportation routes.

Ask For Report Customization:
https://www.imarcgroup.com/request?type=report&id=24198&flag=E

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players. The market includes major domestic pharmaceutical manufacturers as well as multinational companies operating across innovative medicines, generics, biotechnology, consumer healthcare, and specialty therapies.

Recent News and Developments in Turkey Pharmaceutical Market:

• September 2025: Abdi İbrahim and Biogen announced a strategic partnership for the distribution of Biogen medicines for neurological and rare diseases in Türkiye. The collaboration aims to improve access to innovative therapies for patients with complex neurological and rare conditions.

• October 2025: Abdi İbrahim expanded its biotechnology portfolio by introducing its first ophthalmology biosimilar in Türkiye. The company highlighted applications in serious eye conditions, including age-related macular degeneration and diabetic macular edema. The ophthalmology biotechnology market in Türkiye was estimated at approximately USD 53 million based on company-reported market data.

• April 2026: Nobel İlaç announced a new regional R&D and manufacturing investment in Kazakhstan, strengthening its international production and expansion strategy. The company also received recognition for its export performance in the pharmaceutical category.

• June 2026: Türkiye's Ministry of Industry and Technology reported that healthcare investments supported through incentive programs included projects covering biosimilar medicines, oncology treatments, autoimmune medicines, and innovative generics. The supported projects exceeded TRY 23 billion in total investment value.

• July 2026: The Pharmaceuticals Industry Employers' Association reported ongoing industry analysis covering pharmaceutical market developments, pricing and exchange-rate movements, foreign trade, and industrial production, reflecting continued attention to market access, manufacturing, and supply conditions.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us
IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-201971-6302

This release was published on openPR.